Bristol-Myers Squibb committed to boosting research presence, impact

Bristol-Myers Squibb grows R&D
Bristol-Myers Squibb grows R&D | Courtesy of
Bristol-Myers Squibb said this week that it has taken the next steps in expanding its research-and-development unit to facilitate world-class innovations and breakthroughs.

The company is building a new state-of-the-art research facility in Cambridge, Massachusetts, and has been expanding another facility in the San Francisco Bay Area.

The Cambridge facility is scheduled to be operational in 2018. The San Francisco site expansion is scheduled to be completed in 2016 and will add 61,000 square feet of office and laboratory space to the Woodside Technology Park life science campus.

The company, the scientific community and the local economies anticipate growth thanks to these expansions.

"In addition to investments in central New Jersey, our new location in Cambridge and our expanding presence in the San Francisco Bay area positions the company and our scientists in the heart of vibrant ecosystems of world-class science, innovation and business opportunities, which offer ideal environments for fostering external collaboration," Francis Cuss, executive vice president and chief scientific officer at  Bristol-Myers Squibb, said. "Ultimately, our goal is to continue to accelerate the translation of scientific knowledge and insights into the next wave of potentially transformational medicines for patients with serious diseases."

Organizations in this Story

Bristol-Myers Squibb

Want to get notified whenever we write about Bristol-Myers Squibb ?
Next time we write about Bristol-Myers Squibb, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.